Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for... see more

Recent & Breaking News (NYSE:MRK)

Merck Announces Fifth Round of Global Grants to Tackle Maternal Mortality and Promote Health Equity Worldwide

Business Wire March 2, 2021

Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Metastatic Small Cell Lung Cancer in the US

Business Wire March 1, 2021

U.S. FDA Accepts Merck's Gefapixant New Drug Application for Review

Business Wire March 1, 2021

Merck Animal Health Completes Acquisition of Poultry Sense Limited

Business Wire February 25, 2021

SHAREHOLDER ALERT: WeissLaw LLP Investigates Pandion Therapeutics, Inc.

PR Newswire February 25, 2021

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Pandion Therapeutics, Inc. Buyout

GlobeNewswire February 25, 2021

PANDION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PAND and Encourages Investors to Contact the Firm

GlobeNewswire February 25, 2021

Merck to Acquire Pandion Therapeutics

Business Wire February 25, 2021

Merck to Present at the Cowen 41st Annual Health Care Conference

Business Wire February 24, 2021

Independent Data Monitoring Committee Concludes OlympiA Trial of LYNPARZA® (olaparib) Crossed Superiority Boundary for Invasive Disease-Free Survival vs. Placebo at Planned Interim Analysis

Business Wire February 17, 2021

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Business Wire February 13, 2021

Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results

Business Wire February 4, 2021

Kenneth C. Frazier to Retire as Merck CEO; Board Elects Robert M. Davis as Successor; Frazier to Continue as Executive Chairman

Business Wire February 4, 2021

Dr. Stephen Mayo Elected to Merck Board of Directors

Business Wire February 1, 2021

Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA® (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Business Wire February 1, 2021

Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer

Business Wire January 29, 2021

Merck Announces Second Cohort of Safer Childbirth Cities Organizations Committed to Improving Maternal Health Equity and Reducing Preventable Maternal Deaths in the US

Business Wire January 27, 2021

Merck Announces Second-Quarter 2021 Dividend

Business Wire January 26, 2021

Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021

Business Wire January 26, 2021

European Commission Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer

Business Wire January 26, 2021